Xianchen Liu

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 5

Top Topics

Metastatic Breast Cancer

Tyrosine Kinase

Bone Regeneration

Epidermal Growth Factor Receptor

Top Venues

Patient preference and adherence

This page only lists publications with an associated author ORCID identifier.

Publications

Nicole M Engel-Nitz, Mary G Johnson, Michael P Johnson, Ashley S Cha-Silva, Samantha K Kurosky, Xianchen Liu
Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer. Patient preference and adherence 17 (2023)
Nicole M Engel-Nitz, Mary G Johnson, Michael P Johnson, Ashley S Cha-Silva, Samantha K Kurosky, Xianchen Liu
Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer. Patient preference and adherence 17 (2023)
Nicole M Engel-Nitz, Mary G Johnson, Michael P Johnson, Ashley S Cha-Silva, Samantha K Kurosky, Xianchen Liu
Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer. Patient preference and adherence 17 (2023)
Nicole M Engel-Nitz, Mary G Johnson, Michael P Johnson, Ashley S Cha-Silva, Samantha K Kurosky, Xianchen Liu
Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer. Patient preference and adherence 17 (2023)
Martine C Maculaitis, Xianchen Liu, Oliver Will, Madelyn Hanson, Lynn McRoy, Alexandra Berk, Melissa Crastnopol
Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling. Patient preference and adherence 14 (2020)